Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells

Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells

Tania Mariastella Caputo,1,&ast; Angela Maria Cusano,2,&ast; Sofia Principe,1 Paola Cicatiello,1 Giorgia Celetti,1 Anna Aliberti,1 Alberto Micco,2 Menotti Ruvo,3 Maria Tagliamonte,4 Concetta Ragone,4 Michele Minopoli,5 Maria Vincenza Carriero,5 Luigi Buonaguro,4 Andrea Cusano1,2 1Optoelectro...

Full description

Bibliographic Details
Main Authors:	Caputo TM, Cusano AM, Principe S, Cicatiello P, Celetti G, Aliberti A, Micco A, Ruvo M, Tagliamonte M, Ragone C, Minopoli M, Carriero MV, Buonaguro L, Cusano A
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-07-01
Series:	International Journal of Nanomedicine
Subjects:	poly(lactic-co-glycolic acid) sorafenib emulsion solvent evaporation technique hepatocellular carcinoma optical fiber microfluidics
Online Access:	https://www.dovepress.com/sorafenib-loaded-plga-carriers-for-enhanced-drug-delivery-and-cellular-peer-reviewed-fulltext-article-IJN

Similar Items

Sorafenib and Piperine co-loaded PLGA nanoparticles: Development, characterization, and anti-cancer activity against hepatocellular carcinoma cell line
by: Sulaiman S. Alhudaithi, et al.
Published: (2024-05-01)

Development of High-Loading Trastuzumab PLGA Nanoparticles: A Powerful Tool Against HER2 Positive Breast Cancer Cells
by: Caputo TM, et al.
Published: (2023-11-01)

Formulation and Characterization of Fe<sub>3</sub>O<sub>4</sub>@PEG Nanoparticles Loaded Sorafenib; Molecular Studies and Evaluation of Cytotoxicity in Liver Cancer Cell Lines
by: Mona Ebadi, et al.
Published: (2023-02-01)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
by: Agnieszka Karbownik, et al.
Published: (2020-06-01)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
by: Lingling Guo, et al.
Published: (2023-06-01)

PLGA Nanoparticles Loaded with Sorafenib Combined with Thermosensitive Hydrogel System and Microwave Hyperthermia for Multiple Sensitized Radiotherapy
by: Ziqi Wang, et al.
Published: (2023-02-01)

Comparative Analysis of the Cytotoxic Effect of a Complex of Selenium Nanoparticles Doped with Sorafenib, “Naked” Selenium Nanoparticles, and Sorafenib on Human Hepatocyte Carcinoma HepG2 Cells
by: Elena G. Varlamova, et al.
Published: (2022-06-01)

Pharmacokinetic Drug Interaction Study of Sorafenib and Morphine in Rats
by: Agnieszka Karbownik, et al.
Published: (2021-12-01)

Recurrent Hypoglycemia Triggered by Sorafenib Therapy in a Patient with Hemangiopericytoma
by: Si Won Lee, et al.
Published: (2014-06-01)

Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma
by: Koen G. A. M. Hussaarts, et al.
Published: (2021-01-01)

Antitumor activity of sorafenib on colorectal cancer
by: Turgut Kacan, et al.
Published: (2016-08-01)

Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
by: Ki-Young Huh, et al.
Published: (2021-04-01)

Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma
by: Jialiang Luo, et al.
Published: (2022-10-01)

Anti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cells
by: Yaprak Donmez Cakil, et al.
Published: (2023-01-01)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
by: J.T. Stefano, et al.
Published: (2015-02-01)

Ca<sup>2+</sup>-Dependent Effects of the Selenium-Sorafenib Nanocomplex on Glioblastoma Cells and Astrocytes of the Cerebral Cortex: Anticancer Agent and Cytoprotector
by: Elena G. Varlamova, et al.
Published: (2023-01-01)

Rationalized design to explore the full potential of PLGA microspheres as drug delivery systems
by: Rebeca Martinez-Borrajo, et al.
Published: (2023-12-01)

Apigenin enhances sorafenib anti-tumour efficacy in hepatocellular carcinoma
by: Deepti Singh, et al.
Published: (2024-05-01)

Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
by: Hsu CH, et al.
Published: (2014-06-01)

Sorafenib as an Inhibitor of RUVBL2
by: Nardin Nano, et al.
Published: (2020-04-01)

Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis
by: Vikash Jaiswal, et al.
Published: (2023-12-01)

Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration
by: Wenting Ma, et al.
Published: (2016-10-01)

Antiglioma Potential of Coumarins Combined with Sorafenib
by: Joanna Sumorek-Wiadro, et al.
Published: (2020-11-01)

Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case
by: Yu V Bisovskaya, et al.
Published: (2014-06-01)

Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma
by: Song-Fong Huang, et al.
Published: (2022-09-01)

Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells
by: María José López-Grueso, et al.
Published: (2019-10-01)

Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma
by: Ting Sun, et al.
Published: (2017-11-01)

Purification of glycolytic product from polyethylene terephthalate (pet) waste by a two-stage evaporation process
by: Goh, Hui Wen
Published: (2012)

Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort
by: Olivier Trédan, et al.
Published: (2023-06-01)

The Clinical Significance of Myosteatosis in Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib
by: Min Kyu Kang, et al.
Published: (2024-01-01)

Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines
by: Ya-Ting Yang, et al.
Published: (2022-08-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway
by: Li X, et al.
Published: (2020-09-01)

Sorafenib-induced hand-foot skin reaction
by: Madhvi Trivedi, et al.
Published: (2023-01-01)

Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
by: Azim HA, et al.
Published: (2018-11-01)

Comparison of Inflammatory Indexes in Patients Treated with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Observational Study
by: Havva Yeşil Çınkır, et al.
Published: (2020-04-01)

Multichamber PLGA Microparticles with Enhanced Monodispersity and Encapsulation Efficiency Fabricated by a Batch‐Microfluidic Hybrid Approach
by: Sunghak Choi, et al.
Published: (2023-10-01)

Effects of Sorafenib and Quercetin Alone or in Combination in Treating Hepatocellular Carcinoma: In Vitro and In Vivo Approaches
by: Suzan Abdu, et al.
Published: (2022-11-01)

Adverse Event Profile in Advance Hepatocellular Carcinoma treated with Sorafenib Presenting to CMH Rawalpindi
by: Masaba Masood, et al.
Published: (2023-08-01)